Speakers - Sachs Associates

CONTACTS
Vincent Charlon PhD,
CEO
Zoltan Czigler MBA,
Finance Director
ADDRESS
BioPole III
Route de la Corniche 9B
CH-1066 Epalinges
Switzerland
TELEPHONE
+41 21 651 9220
FAX
+41 21 651 9221
EMAIL
info@anergis.ch
YEAR FOUNDED
2001
Anergis SA
www.anergis.ch
FINANCIAL SUMMARY
CHF 18M round March 2011.
COMPANY PROFILE
ANERGIS SA is a Swiss-based biopharmaceutical company specializing in the discovery and development
of novel ultra-fast specific immunotherapy (also known as “SIT” or “desensitization”) products. Allergy is the
most prevalent and the fastest growing chronic condition in the industrialized world with over 300 million
people affected. Current SIT remains underused due to its long duration (3-5 years of treatment) and safety
risks. ANERGIS develops ultra-fast and safe SIT treatments for allergic patients, which can achieve induction
of tolerance to the allergen in few injections only. ANERGIS possesses a unique know-how and the exclusive
rights to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of
Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire
Vaudois (CHUV). Because ANERGIS COPs are long peptides they present the advantage of being recognized
and processed by the antigen presenting cells of the immune system using similar mechanisms as the original
allergen. This feature, combined with the fact that the COPs reproduce – in separate molecules – the full
amino acid sequence of the allergen, and that overlapping sequences guarantee that all linear epitopes are
present, ensures the high immunogenicity of the COPs. In the past years, ANERGIS has studied proprietary COPs
targeting bee venom and birch pollen allergies both in animals and in humans. These studies have confirmed the
excellent safety (no immediate allergic reaction) and expected immunogenicity (production of specific antibodies
and cytokines against the original allergen) of ANERGIS COPs.
MANAGEMENT
Vincent Charlon, CEO
20+ years global clinical development and management experience
• LS Pharma International, CEO
• Hesperion, CEO
• Hoffmann-La Roche, Clinical Director
Christophe Reymond, CSO
20+ years biology, immunology, patents and start-up experience
• Anergis, CSO/COO
• Dictagène, CSO
• Assist Professor University Lausanne
François Spertini, Medical Expert
20+ years medical practice and research in immunology and allergy
• Assoc. Prof. and Chief Allergy/Immunology
• Lausanne University Hospital (CHUV)
• President & founder of Anergis
Zoltan Czigler, Finance Director
MBA Insead, MSc
• Business and Finance consultant
• Director Finance Kuros Biosurgery AG
• Investment and finance manager, VI Partners
Jean-Paul Rohmer, Business Development
20+ years biotech, pharma business and commercial management
• IDEFI Gestion, Managing Director
• Stallergenes, GM & CEO
• Eli Lilly France, Head Pharma Division
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS